Santen Pharmaceutical SNPHF Stock
Santen Pharmaceutical Price Chart
Santen Pharmaceutical SNPHF Financial and Trading Overview
| Santen Pharmaceutical stock price | 10.53 USD |
| Previous Close | 9.59 USD |
| Open | 9.59 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 9.59 - 9.59 USD |
| 52 Week Range | 6.25 - 9.59 USD |
| Volume | 109 USD |
| Avg. Volume | 549 USD |
| Market Cap | 3.6B USD |
| Beta (5Y Monthly) | 0.344444 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0.53 USD |
| Forward Dividend & Yield | 0.24 (2.48%) |
| Ex-Dividend Date | September 28, 2023 |
| 1y Target Est | N/A |
SNPHF Valuation Measures
| Enterprise Value | -55757062144 USD |
| Trailing P/E | N/A |
| Forward P/E | 0.13737114 |
| PEG Ratio (5 yr expected) | 87.07 |
| Price/Sales (ttm) | 0.012913497 |
| Price/Book (mrq) | 0.012255769 |
| Enterprise Value/Revenue | -0.2 |
| Enterprise Value/EBITDA | -3.938 |
Trading Information
Santen Pharmaceutical Stock Price History
| Beta (5Y Monthly) | 0.344444 |
| 52-Week Change | 34.12% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.59 USD |
| 52 Week Low | 6.25 USD |
| 50-Day Moving Average | 8.83 USD |
| 200-Day Moving Average | 7.88 USD |
SNPHF Share Statistics
| Avg. Volume (3 month) | 549 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 375.58M |
| Float | 367.97M |
| Short Ratio | N/A |
| % Held by Insiders | 3.31% |
| % Held by Institutions | 58.62% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 32 |
| Trailing Annual Dividend Yield | 333.54% |
| 5 Year Average Dividend Yield | 182.00% |
| Payout Ratio | N/A |
| Last Split Factor | 5:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | -5.35% |
| Operating Margin (ttm) | -1.10% |
| Gross Margin | 59.52% |
| EBITDA Margin | 5.07% |
Management Effectiveness
| Return on Assets (ttm) | -0.43% |
| Return on Equity (ttm) | -4.75% |
Income Statement
| Revenue (ttm) | 279.04B USD |
| Revenue Per Share (ttm) | 720.24 USD |
| Quarterly Revenue Growth (yoy) | 12.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | 14.16B USD |
| Net Income Avi to Common (ttm) | -14954999808 USD |
| Diluted EPS (ttm) | -0.15 |
| Quarterly Earnings Growth (yoy) | -85.79% |
Balance Sheet
| Total Cash (mrq) | 58.68B USD |
| Total Cash Per Share (mrq) | 156.25 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.383 |
| Book Value Per Share (mrq) | 782.815 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 37.15B USD |
| Levered Free Cash Flow (ttm) | -12089124864 USD |
Profile of Santen Pharmaceutical
| Country | United States |
| State | N/A |
| City | Osaka |
| Address | Grand Front Osaka Tower A |
| ZIP | 530-8552 |
| Phone | 81 6 7664 8621 |
| Website | https://www.santen.com |
| Industry | Drug Manufacturers-General |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products, including Verkazia, which is used for the treatment of vernal keratoconjunctivitis; STN1008903, which is used for dry eye treatment; Eybelis for the treatment of glaucoma and ocular hypertension; Alesion, an anti-allergy ophthalmic solution; Diquas for the treatment for dry eye syndrome; and glaucoma products, such as Tapros, Tapcom, PRESERFLO MicroShunt, and ROCK inhibitor products. The company also developing various pharmaceutical products to treat glaucoma, such as STN1014000, which is in clinical preparation; STN1012600, which is in Phase II clinical trial; STN1011101, STN1013001, and STN1013900, which are in Phase III clinical trial; STN1011402, which is in Phase III clinical trial to treat allergies; STN1010904, which is in Phase II clinical trial to treat fuchs endothelial corneal dystrophy; STN1010905, which is in Phase II clinical trial to treat meibomian gland dysfunction; and STN1013600, which is in Phase I clinical trial to treat presbyopia. In addition, it provides STN1012701, which is in Phase III clinical trial to treat myopia; STN1013800, which is in clinical preparation to treat ptosis; STN6000100, which is in clinical preparation to treat retinitis pigmentosa; STN1013400, which is in Phase I clinical trial to treat myopia; and STN1012700, which is in Phase I clinical trial to treat myopia. Further, it offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Q&A For Santen Pharmaceutical Stock
What is a current SNPHF stock price?
Santen Pharmaceutical SNPHF stock price today per share is 10.53 USD.
How to purchase Santen Pharmaceutical stock?
You can buy SNPHF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Santen Pharmaceutical?
The stock symbol or ticker of Santen Pharmaceutical is SNPHF.
Which industry does the Santen Pharmaceutical company belong to?
The Santen Pharmaceutical industry is Drug Manufacturers-General.
How many shares does Santen Pharmaceutical have in circulation?
The max supply of Santen Pharmaceutical shares is 341.36M.
What is Santen Pharmaceutical Price to Earnings Ratio (PE Ratio)?
Santen Pharmaceutical PE Ratio is 19.86792600 now.
What was Santen Pharmaceutical earnings per share over the trailing 12 months (TTM)?
Santen Pharmaceutical EPS is 0.53 USD over the trailing 12 months.
Which sector does the Santen Pharmaceutical company belong to?
The Santen Pharmaceutical sector is Healthcare.